Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management.

BACKGROUND

Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient's outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC.

METHODS

Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed.

RESULTS

Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes ( = 0.015) and number of mutations ( = 0.015) on cfDNA. Number of mutated genes ( = 0.001), detected mutations ( = 0.001) in cfDNA and ratio (number of mutations/cfDNA) ( = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank = 0.042).

CONCLUSIONS

In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients.